Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 11% – Should You Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares were down 11% during mid-day trading on Thursday . The company traded as low as GBX 676 and last traded at GBX 676. 21,518 shares were traded during trading, a decline of 12% from the average session volume of 24,533 shares. The stock had previously closed at GBX 759.50.

Hemogenyx Pharmaceuticals Stock Performance

The company’s 50 day moving average price is GBX 752.05 and its 200-day moving average price is GBX 828.23. The stock has a market cap of £45.97 million, a P/E ratio of -3.96 and a beta of 1.53. The company has a debt-to-equity ratio of 167.66, a quick ratio of 6.72 and a current ratio of 1.38.

Hemogenyx Pharmaceuticals (LON:HEMO) last released its quarterly earnings results on Thursday, April 30th. The company reported GBX (170.60) earnings per share for the quarter.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.